David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions.…
The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that…
With the global market for cell and gene therapy (CGT) products set to skyrocket in the coming years, Hong Kong is looking to get in on the action with the…
Danish allergy specialist ALK will have a new CEO in 2024, with current incumbent Carsten Hellmann set to step down after a seven-year spell in the hot seat. Hellmann, 59,…
Country managers from three leading medtech multinationals give their take on the key access challenges facing medical device companies in Greece. New Access Models “While some value-based procurement agreements…
One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of…
Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some…
MSD GCC’s new memorandum of understanding (MoU) with The Department of Health Abu Dhabi (DoH) aims to advance research into breast and lung cancer. The deal, signed at the BIO…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
See our Cookie Privacy Policy Here
